AliveGen USA, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative biotherapeutics aimed at addressing significant unmet medical needs. The company focuses on a range of serious health conditions, including muscle wasting disorders, obesity, cardiometabolic diseases, and various forms of cancer. Their mission is to enhance patient care and quality of life through the creation of effective and safe therapies. To this end, AliveGen is actively developing a pipeline of next-generation clinical candidates that leverage advanced biotechnology.

Currently, AliveGen's R&D pipeline includes several promising candidates, such as ALG-801, which has successfully completed Phase 1a and 1b clinical trials. The company is also advancing ALG-802 through preclinical and CMC (Chemistry, Manufacturing, and Controls) development, alongside multiple novel candidates that are in preclinical stages. This strategic focus on innovative therapeutic solutions underscores AliveGen's commitment to addressing complex health challenges and improving treatment outcomes for patients suffering from various debilitating diseases.

United States

They are focused on the discovery and development of novel biotherapeutics to combat the debilitating muscle and bone loss and the loss of functional capacity, as occurs in various neuromuscular diseases, cancer cachexia, congestive heart failure, geriatric sarcopenia and frailty, as well as in other chronic diseases, for which no approved therapies are currently available.

AliveGen

Company Details